Samsung Pharm (001360) — Financial Flexibility Index
Samsung Pharm (001360) has a Financial Flexibility Index of -0.05x as of September 2025. Free cash flow of ₩-2.26 Billion (operating CF ₩-2.29 Billion minus capex ₩30.00 Million) represents 0% of total liabilities (₩44.04 Billion). Check strategic asset allocation of Samsung Pharm to assess the company's strategic physical and investment asset allocation.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Samsung Pharm Financial Flexibility Index (2012–2024)
Historical Financial Flexibility Index trend for Samsung Pharm across 12 annual periods. See 001360 working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Annual Financial Flexibility Index for Samsung Pharm (2012–2024)
Year-by-year free cash flow to debt coverage for Samsung Pharm. For the full company profile including market capitalisation, see 001360 market cap overview.
| Year | Flexibility Index | Free Cash Flow (KRW) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | -0.75x | ₩-16.91 Billion | ₩-17.30 Billion | ₩22.60 Billion | ▲ +20.0% |
| 2023 | -0.94x | ₩-14.88 Billion | ₩-27.66 Billion | ₩15.89 Billion | ▼ -1380.1% |
| 2022 | 0.07x | ₩1.12 Billion | ₩-1.91 Billion | ₩15.32 Billion | ▲ +142.9% |
| 2021 | -0.17x | ₩-3.10 Billion | ₩-7.16 Billion | ₩18.19 Billion | ▼ -310.3% |
| 2020 | 0.08x | ₩4.60 Billion | ₩-2.55 Billion | ₩56.81 Billion | ▼ -81.8% |
| 2019 | 0.45x | ₩11.45 Billion | ₩-2.43 Billion | ₩25.70 Billion | ▲ +430.4% |
| 2018 | -0.13x | ₩-3.91 Billion | ₩-6.52 Billion | ₩28.98 Billion | ▼ -172.2% |
| 2017 | 0.19x | ₩11.26 Billion | ₩5.15 Billion | ₩60.33 Billion | ▼ -55.2% |
| 2016 | 0.42x | ₩23.29 Billion | ₩-9.94 Billion | ₩55.91 Billion | ▲ +357.0% |
| 2015 | 0.09x | ₩7.66 Billion | ₩-4.20 Billion | ₩83.98 Billion | ▲ +127.1% |
| 2014 | -0.34x | ₩-11.49 Billion | ₩-13.58 Billion | ₩34.12 Billion | ▼ -165.2% |
| 2012 | -0.13x | ₩-8.68 Billion | ₩-11.13 Billion | ₩68.31 Billion | — |